JS

Jeena Sikho Lifecare Ltd

Q4 FY26Leisure Services

Jeena Sikho Lifecare Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price505
Market cap₹7.2K Cr
P/E32.4
Updated23 Aug 2026
Read4 min read

The short version

Current operational beds: 2,300; long-term goal to expand to 7,000-10,000 beds in 3-5 years. Jeena Sikho Lifecare Limited targets a 4x to 5x increase in PAT over the next 4 years.

From Jeena Sikho Lifecare Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Current operational beds: 2,300; long-term goal to expand to 7,000-10,000 beds in 3-5 years.
  • Ability to increase 2,000 beds within 9-12 months as needed, pending customer demand growth.
  • Revenue target: INR 3,000 crores in 3-5 years, with balanced services and product mix (~50% each).
  • Strategy focuses on preventive healthcare awareness to shift Indian mindset from curative to preventive.
  • Target to admit 140,000 patients annually to generate around INR 1,400-1,500 crores turnover (0.01% of population).
  • Planned product launches for BP, sugar, kidney, liver, depression, pregnancy to boost sales further.
  • Product sales grew by INR 3 crores last month; repeat business in hospital at 26%, product side 34%.
  • Minimum PAT guidance for FY27: INR 300 crores.
  • Expansion and promotional activities (TV shows) ongoing to increase patient inflow and volumes.

Profitability & Margins

See what Jeena Sikho Lifecare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Manish Grover emphasized a significant future investment focus on research, aiming to build a large research wing within the next 2 years. This is expected to attract global patients from the US, UK, Middle East, and Australia for treatment and prevention.
  • Current capital expenditure includes new asset additions of INR32 crores and transfer of INR10 crores from Work In Progress (WIP), totaling INR42 crores.
  • The company plans bed capacity expansions, with the ability to add 2,000 beds within 9 months to a year as demand grows.
  • Special new projects launching soon include pregnancy preparation products and Ayurvedic approaches to preventive care.
  • The capital efficiency of the healthcare model is highlighted, with setup costs per bed at INR3-4 lakh and a payback period under 6 months.
  • Future strategic growth aims to list 10-15 similar companies to create a preventive healthcare market in India.

Top-ranked in Leisure Services

Ranked on what management guided this quarter

5x potential
Rev 2Mar 1
2Jubilant Food.
Rev 2Mar 3
3
Rev 2Mar 3
4
Rev 2Mar 3
5
Rev 2Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jeena Sikho Lifecare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Manish Grover mentioned having ready infrastructure to increase 2,000 beds within 9 months to a year whenever demand arises.
  • The team is currently focused on creating customer readiness through awareness campaigns (TV shows like "Laughter Chefs," "MasterChef," "Khatron Ke Khiladi") to shift public mindset from curative to preventive care.
  • Advance bookings/payments from preventive customers were temporarily delayed due to geopolitical concerns (Iran-America war fears) but have recently started normalizing with higher footfall.
  • As of May 31, there are advances of around INR 8 crores carried forward to June.
  • New product launches and marketing efforts are ongoing to drive product repeat orders and demand.
  • The company is poised for rapid scaling as soon as the preventive care narrative fully penetrates the market, expecting significant bed utilization growth.

Jeena Sikho Lifecare Ltd — Quarterly revenue & net profit

Revenue Net profit
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹222 Cr, net profit ₹67 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Leisure Services this season

  • Grand Continent Hotels Ltd (Q4 FY26)

    . Key concall takeaways from Grand Continent's Q4 FY26 earnings call — and how it ranks against sector peers.

  • Suba Hotels Ltd (Q4 FY26)

    Growth driven by a combination of new key additions, increasing occupancy (currently around 68.5%), and raising Average Room Rates (ARR). Key concall takeaways…

  • Wonderla Holidays Ltd (Q4 FY26)

    Marketing and A&P spend is to be maintained at 7-8% to support growth. Key concall takeaways from Wonderla Holidays Ltd's Q4 FY26 earnings call — and how it…

  • Westlife Foodworld Ltd (Q4 FY26)

    Price increases are typically 2-4% per annum but no immediate hikes are planned given current inflation management. Key concall takeaways from Westlife…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Jeena Sikho Lifecare Ltd Q4 FY26 results?

Current operational beds: 2,300; long-term goal to expand to 7,000-10,000 beds in 3-5 years. Jeena Sikho Lifecare Limited targets a 4x to 5x increase in PAT over the next 4 years.

What is Jeena Sikho Lifecare Ltd share price analysis?

Jeena Sikho Lifecare Ltd currently shows a neutral. The stock trades at a P/E of 32.4 with a market cap of ₹7,200 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jeena Sikho Lifecare Ltd planning capital expenditure?

Manish Grover emphasized a significant future investment focus on research, aiming to build a large research wing within the next 2 years.

Keep Jeena Sikho Lifecare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.